Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 30Terminated 7Withdrawn 2Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 2Sarcoma 2Other hematologic neoplasm 2Dermatologic 2Breast 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 65Nivolumab 58Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 23darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16avelumab 14Radiotherapy, Intensity-Modulated 14Pluvicto 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × sargramostim × Genitourinary × Clear all
NCT03600350 2026-06-01

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

University of Wisconsin, Madison

Phase 2 Active not recruiting
19 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡